Company intelligence / Profile preview
Geneos Therapeutics
- Ownership
- Private
- Development stage
- Other
Overview
Geneos Therapeutics has demonstrated positive safety, immunogenicity, and efficacy results in its lead Phase 1/2 GT‑30 trial of a personalized neoantigen vaccine plus IL‑12 and pembrolizumab in advanced HCC. The study met its primary endpoints and showed objective responses including complete responses and secondary resectability. Data were published in Nature Medicine and presented at AACR 2024. Planning for a potentially registrational trial is underway.
- Therapeutic areas
- Oncology
- Modalities
- DNA-based personalized therapeutic cancer vaccines (PTCVs)DNA plasmid encoded cytokine adjuvant (IL-12)Combination with immune checkpoint inhibitors (e.g., pembrolizumab)
- Industry
- Biotech
Drug pipeline
8 assets7 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Geneos Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Geneos Therapeutics.